TW200621259A - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
TW200621259A
TW200621259A TW094130101A TW94130101A TW200621259A TW 200621259 A TW200621259 A TW 200621259A TW 094130101 A TW094130101 A TW 094130101A TW 94130101 A TW94130101 A TW 94130101A TW 200621259 A TW200621259 A TW 200621259A
Authority
TW
Taiwan
Prior art keywords
chemical compounds
manufacture
relates
cancer
activity
Prior art date
Application number
TW094130101A
Other languages
English (en)
Inventor
Brian Aquila
Paul Lyne
Timothy Pontz
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TW200621259A publication Critical patent/TW200621259A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW094130101A 2004-09-01 2005-09-02 Chemical compounds TW200621259A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60653504P 2004-09-01 2004-09-01

Publications (1)

Publication Number Publication Date
TW200621259A true TW200621259A (en) 2006-07-01

Family

ID=35149373

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094130101A TW200621259A (en) 2004-09-01 2005-09-02 Chemical compounds

Country Status (16)

Country Link
US (1) US20090054469A1 (zh)
EP (1) EP1789400A1 (zh)
JP (1) JP2008511600A (zh)
KR (1) KR20070055575A (zh)
CN (1) CN101010303A (zh)
AR (1) AR050545A1 (zh)
AU (1) AU2005278961A1 (zh)
BR (1) BRPI0514679A (zh)
CA (1) CA2577278A1 (zh)
IL (1) IL181213A0 (zh)
MX (1) MX2007002433A (zh)
NO (1) NO20071245L (zh)
TW (1) TW200621259A (zh)
UY (1) UY29092A1 (zh)
WO (1) WO2006024836A1 (zh)
ZA (1) ZA200701366B (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
DK1957461T3 (en) 2005-11-14 2016-12-19 Genentech Inc Bisamidhæmmere the hedgehog-signalling
CN101415688A (zh) * 2006-04-05 2009-04-22 阿斯利康(瑞典)有限公司 具有b-raf抑制活性的喹唑啉酮衍生物
CN101421253A (zh) * 2006-04-18 2009-04-29 阿斯利康(瑞典)有限公司 喹唑啉-4-酮衍生物、其制备方法及含有它们的药用组合物
US20100216791A1 (en) * 2006-08-17 2010-08-26 Astrazeneca Pyridinylquinazolinamine derivatives and their use as b-raf inhibitors
US20100120717A1 (en) 2006-10-09 2010-05-13 Brown Jason W Kinase inhibitors
WO2009111280A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
CN102015707A (zh) * 2008-02-29 2011-04-13 阵列生物制药公司 Raf抑制剂化合物及其使用方法
CA2716947A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
CL2009000448A1 (es) * 2008-02-29 2009-11-27 Genentech Inc Compuestos derivados de 3-sulfonilamino-n-(1h-pirazolo-[3,4-b]piridin-5il)benzamida; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento del cancer, tal como sarcoma, carcinoma, adenoma, entre otros.
US9084781B2 (en) 2008-12-10 2015-07-21 Novartis Ag MEK mutations conferring resistance to MEK inhibitors
JP5985401B2 (ja) 2010-03-09 2016-09-06 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 第一の癌療法に対する耐性を現に有するか、または、そのような耐性を生じる患者において癌を診断および治療する方法
WO2011147764A1 (en) 2010-05-28 2011-12-01 N.V. Organon Thieno (2, 3b) pyrazine compounds as b - raf inhibitors
AU2011264833B2 (en) 2010-06-09 2014-07-03 Dana-Farber Cancer Institute, Inc. A MEK 1 mutation conferring resistance to RAF and MEK inhibitors
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
WO2014160438A1 (en) * 2013-03-13 2014-10-02 Bioasis Technologies Inc. Fragments of p97 and uses thereof
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
JP6038212B2 (ja) * 2015-03-18 2016-12-07 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 甲状腺刺激ホルモン受容体（ｔｓｈｒ）の低分子量アゴニスト
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2444605A (en) * 1945-12-15 1948-07-06 Gen Aniline & Film Corp Stabilizers for photographic emulsions
GB9623833D0 (en) * 1996-11-16 1997-01-08 Zeneca Ltd Chemical compound
HUP0103019A3 (en) * 1998-08-04 2002-01-28 Astrazeneca Ab Amide derivatives useful as inhibitors of the production of cytokines, process for producing them and pharmaceutical compositions containing them
GB0005357D0 (en) * 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
IL164302A0 (en) * 2002-03-29 2005-12-18 Chiron Corp Substituted benzazoles and use thereof as raf kinase inhibitors

Also Published As

Publication number Publication date
NO20071245L (no) 2007-05-24
BRPI0514679A (pt) 2008-06-17
EP1789400A1 (en) 2007-05-30
CA2577278A1 (en) 2006-03-09
WO2006024836A1 (en) 2006-03-09
AU2005278961A1 (en) 2006-03-09
MX2007002433A (es) 2007-05-04
AR050545A1 (es) 2006-11-01
ZA200701366B (en) 2008-09-25
CN101010303A (zh) 2007-08-01
US20090054469A1 (en) 2009-02-26
IL181213A0 (en) 2007-07-04
UY29092A1 (es) 2006-04-28
JP2008511600A (ja) 2008-04-17
KR20070055575A (ko) 2007-05-30

Similar Documents

Publication Publication Date Title
TW200634003A (en) Chemical compounds
TW200616974A (en) Chemical compounds
MX2007008924A (es) Compuestos quimicos.
TW200621259A (en) Chemical compounds
TW200621730A (en) Chemical compounds
TW200635899A (en) Chemical compounds
TW200736234A (en) Chemical compounds
WO2007113558A8 (en) Quinazolinone derivatives having b-raf inhibitory activity
WO2007071963A3 (en) Quinazoline derivatives, process for their preparation and their use as anti-cancer agents
MX2009004908A (es) Compuestos quimicos.
MX2009004906A (es) Sulfonamidas heterociclicas que tienen actividad antagonistica del edg-1.
MX2010007523A (es) Nuevos derivados de pirazolo[3,4-d]pirimidina como farmacos anticancer.
MX2008013212A (es) 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r.
WO2008068507A3 (en) 2 -phenylamino, 6- (pyrid-3-yl) quinazoline derivatives as raf-protein kinase inhibitors in cancer treatment
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
TW200640908A (en) Chemical compounds
SG148177A1 (en) Novel cis-imidazolines
MY143565A (en) Novel fluorocglycoside derivatives of pyrazoles: medicaments containing these compounds, and the use thereof
TW200615266A (en) Organic compounds
BRPI0518126A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf e um efeito anti-cáncer em um animal de sangue quente, e para tratar uma doença ou condição
TW200621762A (en) Novel compounds
UA85708C2 (ru) Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей
TW200635878A (en) Hydroxybiphenylcarboxylic acids and derivatives, processes for preparing them and their use
TW200731975A (en) Novel combinations of medicaments for the treatment of respiratory diseases
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання